Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women Clinical Trial
Official title:
Influence of Zoledronic Acid on Bone Mineral Density and Bone Ultrasonometry in Premenopausal Women With Hormone Receptor Negative Breast Cancer and Adjuvant Chemotherapeutic Treatment
Breast cancer and osteoporosis are two of the most frequent diseases in women. Estrogen may
be associated with bone loss and the risk of breast cancer because of its potent effects on
the mitotic activity of breast epithelium and on bone turnover.
This study is will assess the safety and efficacy of Zoledronic acid 4 mg, given every 3
months over 24 months, in improving bone mineral density in premenopausal women with hormone
receptor negative breast cancer and adjuvant chemotherapeutic treatment compared to placebo.
This study is not recruiting patients in the United States.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment